An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs and tissues. Mesenchymal stem cells (MSCs) are considered a good source for autoimmune disease and hematological disease therapy. This review will summarize the efficacy, safety, and mechanisms of MSC therapy fo...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2021/2168595 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563684739645440 |
|---|---|
| author | Qian Yang Yiping Liu Guangyong Chen Wancong Zhang Shijie Tang Tianbiao Zhou |
| author_facet | Qian Yang Yiping Liu Guangyong Chen Wancong Zhang Shijie Tang Tianbiao Zhou |
| author_sort | Qian Yang |
| collection | DOAJ |
| description | Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs and tissues. Mesenchymal stem cells (MSCs) are considered a good source for autoimmune disease and hematological disease therapy. This review will summarize the efficacy, safety, and mechanisms of MSC therapy for SLE. MSC therapy can reduce anti-dsDNA, antinuclear antigen (ANA), proteinuria, and serum creatinine in SLE patients. In animal models of SLE, MSC therapy also indicates that it could reduce anti-dsDNA, ANA, proteinuria, and serum creatinine and ameliorate renal pathology. There are no serious adverse events, treatment-related mortality, or tumor-related events in SLE patients after stem cell treatment. MSCs can inhibit inflammatory factors, such as MCP-1 and HMGB-1, and inhibit inflammation-related signaling pathways, such as the NF-κB, JAK/STAT, and Akt/GSK3β signaling pathways, to alleviate the lesions in SLE. |
| format | Article |
| id | doaj-art-10f26b4156cd4da2aabe488c7c8c21ea |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-10f26b4156cd4da2aabe488c7c8c21ea2025-02-03T01:12:53ZengWileyStem Cells International1687-966X1687-96782021-01-01202110.1155/2021/21685952168595An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus ErythematosusQian Yang0Yiping Liu1Guangyong Chen2Wancong Zhang3Shijie Tang4Tianbiao Zhou5Department of Nephrology, Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, ChinaDepartment of Nephrology, Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, ChinaDepartment of Nephrology, Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, ChinaDepartment of Plastic Surgery and Burn Center, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, ChinaDepartment of Plastic Surgery and Burn Center, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, ChinaDepartment of Nephrology, Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, ChinaSystemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs and tissues. Mesenchymal stem cells (MSCs) are considered a good source for autoimmune disease and hematological disease therapy. This review will summarize the efficacy, safety, and mechanisms of MSC therapy for SLE. MSC therapy can reduce anti-dsDNA, antinuclear antigen (ANA), proteinuria, and serum creatinine in SLE patients. In animal models of SLE, MSC therapy also indicates that it could reduce anti-dsDNA, ANA, proteinuria, and serum creatinine and ameliorate renal pathology. There are no serious adverse events, treatment-related mortality, or tumor-related events in SLE patients after stem cell treatment. MSCs can inhibit inflammatory factors, such as MCP-1 and HMGB-1, and inhibit inflammation-related signaling pathways, such as the NF-κB, JAK/STAT, and Akt/GSK3β signaling pathways, to alleviate the lesions in SLE.http://dx.doi.org/10.1155/2021/2168595 |
| spellingShingle | Qian Yang Yiping Liu Guangyong Chen Wancong Zhang Shijie Tang Tianbiao Zhou An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus Stem Cells International |
| title | An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus |
| title_full | An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus |
| title_fullStr | An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus |
| title_full_unstemmed | An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus |
| title_short | An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus |
| title_sort | overview of the safety efficiency and signal pathways of stem cell therapy for systemic lupus erythematosus |
| url | http://dx.doi.org/10.1155/2021/2168595 |
| work_keys_str_mv | AT qianyang anoverviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT yipingliu anoverviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT guangyongchen anoverviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT wancongzhang anoverviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT shijietang anoverviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT tianbiaozhou anoverviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT qianyang overviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT yipingliu overviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT guangyongchen overviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT wancongzhang overviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT shijietang overviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus AT tianbiaozhou overviewofthesafetyefficiencyandsignalpathwaysofstemcelltherapyforsystemiclupuserythematosus |